🇺🇸 MTL-CEBPA in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 1
Most-reported reactions
- Pulmonary Embolism — 1 report (100%)
Frequently asked questions
Is MTL-CEBPA approved in United States?
MTL-CEBPA does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for MTL-CEBPA in United States?
Mina Alpha Limited is the originator. The local marketing authorisation holder may differ — check the official source linked above.